Harmony Biosciences Holdings (HRMY) Change in Accured Expenses (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Change in Accured Expenses data on file, last reported at -$46.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 746.48% year-over-year to -$46.2 million; the trailing twelve-month figure through Mar 2026 stood at $27.3 million (up 87.11% YoY), and the FY2025 full-year result was $68.0 million, up 476.27% from the prior year.
• Change in Accured Expenses fell to -$46.2 million in Q1 2026, from $52.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $52.5 million in Q4 2025 to a low of -$46.2 million in Q1 2026.
• A 5-year average of $5.9 million and a median of $3.1 million in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses soared 535.86% in 2022 and tumbled 746.48% in 2026, its largest moves.
• Tracing HRMY's Change in Accured Expenses over 5 years: stood at -$22.8 million in 2022, then soared by 235.23% to $30.8 million in 2023, then sank by 59.13% to $12.6 million in 2024, then surged by 317.11% to $52.5 million in 2025, then plunged by 188.05% to -$46.2 million in 2026.
• Business Quant data shows HRMY's Change in Accured Expenses at -$46.2 million in Q1 2026, $52.5 million in Q4 2025, and $28.0 million in Q3 2025.